MLH1 and lung adenocarcinoma: Secondly, our findings suggest that the combination of EGFR-TKIs with other anti-cancer therapeutics may be a rational treatment strategy for patients with lung adenocarcinomas concurrently harboring a somatic EGFR L858R mutation in the tumor and a germline MLH1 V384D polymorphism.